» Articles » PMID: 24740290

Outcomes of Acute Chest Syndrome in Adult Patients with Sickle Cell Disease: Predictors of Mortality

Overview
Journal PLoS One
Date 2014 Apr 18
PMID 24740290
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: Adults with sickle cell disease(SCD) are a growing population. Recent national estimates of outcomes in acute chest syndrome(ACS) among adults with SCD are lacking. We describe the incidence, outcomes and predictors of mortality in ACS in adults. We hypothesize that any need for mechanical ventilation is an independent predictor of mortality.

Methods: We performed a retrospective analysis of the Nationwide Inpatient Sample(2004-2010),the largest all payer inpatient database in United States, to estimate the incidence and outcomes of ACS needing mechanical ventilation(MV) and exchange transfusion(ET) in patients >21 years. The effects of MV and ET on outcomes including length of stay(LOS) and in-hospital mortality(IHM) were examined using multivariable linear and logistic regression models respectively. The effects of age, sex, race, type of sickle cell crisis, race, co-morbid burden, insurance status, type of admission, and hospital characteristics were adjusted in the regression models.

Results: Of the 24,699 hospitalizations, 4.6% needed MV(2.7% for <96 hours, 1.9% for ≥96 hours), 6% had ET, with a mean length of stay(LOS) of 7.8 days and an in-hospital mortality rate(IHM) of 1.6%. There was a gradual yearly increase in ACS hospitalizations that needed MV(2.6% in 2004 to 5.8% in 2010). Hb-SS disease was the phenotype in 84.3% of all hospitalizations. After adjusting for a multitude of patient and hospital related factors, patients who had MV for <96 hours(OR = 67.53,p<0.01) or those who had MV for ≥96 hours(OR = 8.73,p<0.01) were associated with a significantly higher odds for IHM when compared to their counterparts. Patients who had MV for ≥96 hours and those who had ET had a significantly longer LOS in-hospitals(p<0.001).

Conclusion: In this large cohort of hospitalized adults with SCD patients with ACS, the need for mechanical ventilation predicted higher mortality rates and increased hospital resource utilization. Identification of risk factors may enable optimization of outcomes.

Citing Articles

Pulmonary Function after Nonmyeloablative Hematopoietic Cell Transplant for Sickle Cell Disease.

Ruhl A, Shalhoub R, Jeffries N, Limerick E, Leonard A, Barochia A Ann Am Thorac Soc. 2024; 21(10):1398-1406.

PMID: 39189784 PMC: 11451896. DOI: 10.1513/AnnalsATS.202309-771OC.


Lipid and hemolysis parameters predicting acute chest syndrome in adulthood with sickle cell disease.

Feugray G, Grall M, Dumesnil C, Brunel V, Benhamou Y, Quillard Muraine M Lipids Health Dis. 2024; 23(1):140.

PMID: 38755670 PMC: 11100209. DOI: 10.1186/s12944-024-02135-8.


Multi-center study on mortality in children, and adults with sickle cell anemia-risk factors and causes of death.

Alkindi S, Al-Jadidi S, Al-Adawi S, Elsadek R, Al Madhani A, Al-Nabhani M Sci Rep. 2024; 14(1):8584.

PMID: 38615021 PMC: 11016086. DOI: 10.1038/s41598-024-58328-9.


Adherence to hydroxyurea and clinical outcomes among children with sickle cell anemia.

Reeves S, Dombkowski K, Peng H, Phan H, Kolenic G, Creary S Pediatr Blood Cancer. 2023; 70(7):e30332.

PMID: 37046404 PMC: 10788073. DOI: 10.1002/pbc.30332.


Homozygous sickle cell disease related mortality in Senegal (2011-2020).

Seck M, Ba O, Faye B, Toure S, Gueye Y, Dieng N EJHaem. 2022; 2(4):711-715.

PMID: 35845188 PMC: 9176000. DOI: 10.1002/jha2.273.


References
1.
Vichinsky E, Neumayr L, Earles A, Williams R, Lennette E, Dean D . Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med. 2000; 342(25):1855-65. DOI: 10.1056/NEJM200006223422502. View

2.
Steinberg M, Barton F, Castro O, Pegelow C, Ballas S, Kutlar A . Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003; 289(13):1645-51. DOI: 10.1001/jama.289.13.1645. View

3.
Quinn C, Rogers Z, Buchanan G . Survival of children with sickle cell disease. Blood. 2004; 103(11):4023-7. PMC: 1828870. DOI: 10.1182/blood-2003-11-3758. View

4.
Stallworth J, Jerrell J, Tripathi A . Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease. Am J Hematol. 2010; 85(10):795-7. DOI: 10.1002/ajh.21772. View

5.
Gladwin M, Vichinsky E . Pulmonary complications of sickle cell disease. N Engl J Med. 2008; 359(21):2254-65. DOI: 10.1056/NEJMra0804411. View